Hubei Goto Biopharm Co.Ltd(300966) 4 disclosed the annual report of 2021 on April 21. The company achieved an operating revenue of 591 million yuan in 2021, with a year-on-year increase of 26.23%; The net profit attributable to the shareholders of the listed company was 783306 million yuan, a year-on-year increase of 46.99%. The company plans to distribute cash dividends of 1.36 yuan (including tax) to all shareholders for every 10 shares.
Hubei Goto Biopharm Co.Ltd(300966) said that during the reporting period, the company actively responded to the market and customer demand, continued to invest in production process and product R & D, increased production investment relying on the advantages of starting materials and products, improved capacity utilization, and steadily increased overall output value and sales revenue.
The annual report shows that Hubei Goto Biopharm Co.Ltd(300966) produced 1319735 tons of steroidal drug raw materials in 2021, with a year-on-year increase of 91.79%; Sales of steroidal drug raw materials were 991.32 tons, with a year-on-year increase of 82.82%.
At the same time, the company always attaches great importance to technological innovation and new product R & D. During the reporting period, R & D investment accounted for 6.28% and technicians accounted for 10.72%.
